ES2487465T1 - Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos - Google Patents

Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos Download PDF

Info

Publication number
ES2487465T1
ES2487465T1 ES12723442.5T ES12723442T ES2487465T1 ES 2487465 T1 ES2487465 T1 ES 2487465T1 ES 12723442 T ES12723442 T ES 12723442T ES 2487465 T1 ES2487465 T1 ES 2487465T1
Authority
ES
Spain
Prior art keywords
cells
cell population
multiple sclerosis
myelin
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES12723442.5T
Other languages
English (en)
Spanish (es)
Inventor
Olga De La Rosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of ES2487465T1 publication Critical patent/ES2487465T1/es
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0637Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22Immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/416Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/13Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352Mesenchymal stem cells
    • C12N2502/1382Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES12723442.5T 2011-05-19 2012-05-18 Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos Pending ES2487465T1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166808 2011-05-19
EP11166808 2011-05-19
PCT/EP2012/059313 WO2012156522A1 (en) 2011-05-19 2012-05-18 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Publications (1)

Publication Number Publication Date
ES2487465T1 true ES2487465T1 (es) 2014-08-20

Family

ID=46149436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12723442.5T Pending ES2487465T1 (es) 2011-05-19 2012-05-18 Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos

Country Status (6)

Country Link
US (1) US20140348808A1 (cg-RX-API-DMAC7.html)
EP (1) EP2710122B1 (cg-RX-API-DMAC7.html)
JP (2) JP2014515258A (cg-RX-API-DMAC7.html)
KR (1) KR20140071277A (cg-RX-API-DMAC7.html)
ES (1) ES2487465T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012156522A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290736B2 (en) 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
FR2976580B1 (fr) * 2011-06-14 2013-05-31 Coatex Sas Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations.
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
JP2021531280A (ja) 2018-03-27 2021-11-18 スミス セラピューティクス インコーポレイテッド 神経変性疾患を処置するためのCAR−Tregベースの治療
CN109913415B (zh) * 2019-03-26 2020-05-22 广东先康达生物科技有限公司 Treg细胞的培养液及其培养方法与应用
CA3230229A1 (en) * 2021-09-03 2023-03-09 Tobias Abel Mog-binding proteins and uses thereof
CN120129527A (zh) * 2022-09-02 2025-06-10 财团法人医药工业技术发展中心 包含间充质干细胞的组合物在缓解骨髓纤维化上的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
EP1715889A4 (en) * 2004-01-08 2008-03-05 Univ California LYMPHOCYTES T REGULATORS SUPPRESSING AUTOIMMUNITY
ES2563955T3 (es) * 2005-08-02 2016-03-16 Centenary Institute Of Cancer Medicine & Cell Biology Método para identificar linfocitos T reguladores
PT1926813T (pt) 2005-09-23 2016-09-06 Consejo Superior Investigacion Populações de células que têm atividade imunorreguladora, método para isolamento e usos
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
CN102459577B (zh) * 2009-05-18 2014-08-20 特拉科斯有限公司 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
JP2018134086A (ja) 2018-08-30
EP2710122A1 (en) 2014-03-26
KR20140071277A (ko) 2014-06-11
EP2710122B1 (en) 2021-03-31
JP6592551B2 (ja) 2019-10-16
JP2014515258A (ja) 2014-06-30
US20140348808A1 (en) 2014-11-27
WO2012156522A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
ES2487465T1 (es) Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos
Wang et al. Mesenchymal stem cell–derived small extracellular vesicles and bone regeneration
ES2927175T3 (es) Método de producción de micropartículas
US20220090008A1 (en) Colony forming medium and use thereof
Chen et al. The application of umbilical cord‐derived MSCs in cardiovascular diseases
Yang et al. Regulatory T cells inhibit microglia activation and protect against inflammatory injury in intracerebral hemorrhage
ES2873877T3 (es) Composiciones y métodos para disminuir una respuesta inmune
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
ES2769778T3 (es) Composiciones inmunomoduladoras
WO2005104755A3 (en) Artificial immune system: methods for making and use
BR112018003031A2 (pt) formulações clínicas
MX2016010171A (es) Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
WO2008073635A3 (en) Automatable artificial immune system (ais)
ES2581277T3 (es) Composición mejorada para inhibir la proliferación de células tumorales
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
Zhang et al. Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats
Parvizi et al. Development of recombinant collagen‐peptide‐based vehicles for delivery of adipose‐derived stromal cells
JP2014515258A5 (cg-RX-API-DMAC7.html)
Hovhannisyan et al. The role of non-immune cell-derived extracellular vesicles in allergy
AR125461A1 (es) Células presentadoras de antígeno recombinante
MX2021007353A (es) Generación de células t sensibilizadas por organoide (opt) con fenotipo de memoria.
WO2019068048A1 (en) INTERMEDIATE NK CELLS DERIVED FROM PLACENTA (PINK) FOR THE TREATMENT OF GLIOBLASTOMA
KR102167819B1 (ko) 코 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas